1. Home
  2. LDI vs ACHV Comparison

LDI vs ACHV Comparison

Compare LDI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$1.01

Market Cap

607.4M

Sector

Finance

ML Signal

HOLD

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$6.10

Market Cap

618.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
ACHV
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.4M
618.0M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
LDI
ACHV
Price
$1.01
$6.10
Analyst Decision
Sell
Strong Buy
Analyst Count
3
3
Target Price
$3.00
$14.67
AVG Volume (30 Days)
1.9M
2.2M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.58
N/A
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$2.38
52 Week High
$5.05
$7.11

Technical Indicators

Market Signals
Indicator
LDI
ACHV
Relative Strength Index (RSI) 36.43 51.78
Support Level N/A $4.09
Resistance Level $1.32 $7.11
Average True Range (ATR) 0.07 0.40
MACD -0.01 -0.05
Stochastic Oscillator 29.45 38.86

Price Performance

Historical Comparison
LDI
ACHV

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Share on Social Networks: